The first-in-class ADC to be FDA-approved for therapy was gemtuzumab ozogamicin (Mylotarg), in 2000 for the treatment of CD33-positive acute myeloid leukemia (AML) (31). This evidence concerns the gene CD33 and acute myeloid leukemia.